JP2013507415A5 - - Google Patents

Download PDF

Info

Publication number
JP2013507415A5
JP2013507415A5 JP2012533589A JP2012533589A JP2013507415A5 JP 2013507415 A5 JP2013507415 A5 JP 2013507415A5 JP 2012533589 A JP2012533589 A JP 2012533589A JP 2012533589 A JP2012533589 A JP 2012533589A JP 2013507415 A5 JP2013507415 A5 JP 2013507415A5
Authority
JP
Japan
Prior art keywords
compound
formula
composition
administered
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2012533589A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013507415A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/065149 external-priority patent/WO2011054620A1/en
Publication of JP2013507415A publication Critical patent/JP2013507415A/ja
Publication of JP2013507415A5 publication Critical patent/JP2013507415A5/ja
Ceased legal-status Critical Current

Links

JP2012533589A 2009-10-12 2010-10-11 Pi3k阻害剤とmek阻害剤の併用 Ceased JP2013507415A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25085209P 2009-10-12 2009-10-12
US61/250,852 2009-10-12
PCT/EP2010/065149 WO2011054620A1 (en) 2009-10-12 2010-10-11 Combinations of a pi3k inhibitor and a mek inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014202819A Division JP5745678B2 (ja) 2009-10-12 2014-10-01 Pi3k阻害剤とmek阻害剤の併用

Publications (2)

Publication Number Publication Date
JP2013507415A JP2013507415A (ja) 2013-03-04
JP2013507415A5 true JP2013507415A5 (cg-RX-API-DMAC10.html) 2014-04-24

Family

ID=43072663

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012533589A Ceased JP2013507415A (ja) 2009-10-12 2010-10-11 Pi3k阻害剤とmek阻害剤の併用
JP2014202819A Expired - Fee Related JP5745678B2 (ja) 2009-10-12 2014-10-01 Pi3k阻害剤とmek阻害剤の併用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014202819A Expired - Fee Related JP5745678B2 (ja) 2009-10-12 2014-10-01 Pi3k阻害剤とmek阻害剤の併用

Country Status (24)

Country Link
US (1) US20110086837A1 (cg-RX-API-DMAC10.html)
EP (1) EP2488178B1 (cg-RX-API-DMAC10.html)
JP (2) JP2013507415A (cg-RX-API-DMAC10.html)
KR (1) KR101489045B1 (cg-RX-API-DMAC10.html)
CN (1) CN102740851B (cg-RX-API-DMAC10.html)
AR (1) AR078588A1 (cg-RX-API-DMAC10.html)
AU (1) AU2010314287A1 (cg-RX-API-DMAC10.html)
BR (1) BR112012008483A2 (cg-RX-API-DMAC10.html)
CA (1) CA2776944A1 (cg-RX-API-DMAC10.html)
CL (1) CL2012000913A1 (cg-RX-API-DMAC10.html)
CO (1) CO6531463A2 (cg-RX-API-DMAC10.html)
CR (1) CR20120173A (cg-RX-API-DMAC10.html)
EC (1) ECSP12011865A (cg-RX-API-DMAC10.html)
ES (1) ES2609767T3 (cg-RX-API-DMAC10.html)
IL (1) IL219105A0 (cg-RX-API-DMAC10.html)
MA (1) MA33974B1 (cg-RX-API-DMAC10.html)
MX (1) MX345155B (cg-RX-API-DMAC10.html)
NZ (1) NZ599939A (cg-RX-API-DMAC10.html)
PE (1) PE20121816A1 (cg-RX-API-DMAC10.html)
PH (1) PH12012500709A1 (cg-RX-API-DMAC10.html)
RU (1) RU2563193C2 (cg-RX-API-DMAC10.html)
TW (1) TWI428336B (cg-RX-API-DMAC10.html)
WO (1) WO2011054620A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201202618B (cg-RX-API-DMAC10.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110028651A (ko) 2008-07-11 2011-03-21 노파르티스 아게 (a) 포스포이노시타이드 3-키나제 억제제 및 (b) ras/raf/mek 경로의 조절제의 조합물
HRP20150947T1 (hr) 2009-01-08 2015-10-09 Curis, Inc. Inhibitori fosfoinositid 3-kinaze sa skupinom koja veže cink
PH12012501361A1 (en) 2009-12-31 2012-10-22 Centro Nac De Investigaciones Oncologicas Cnio Tricyclic compounds for use as kinase inhibitors
WO2012098387A1 (en) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
LT3111938T (lt) 2011-04-01 2019-06-25 Curis, Inc. Fosfoinozitido 3-kinazės inhibitorius su cinko rišamąja dalimi
BR112014002353B1 (pt) 2011-08-01 2022-09-27 Genentech, Inc Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
RU2607944C2 (ru) * 2011-08-31 2017-01-11 Новартис Аг Синергические композиции ингибиторов pi3k и мек
CA2849331A1 (en) 2011-10-13 2013-04-18 Genentech, Inc. Treatment of pharmacological-induced hypochlorhydria
EP2776051A4 (en) * 2011-10-28 2015-06-17 Hoffmann La Roche THERAPEUTIC COMBINATIONS AND METHOD FOR THE TREATMENT OF MELANOMA
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
WO2013152165A1 (en) * 2012-04-06 2013-10-10 Sanofi Methods for treating cancer using pi3k inhibitor and mek inhibitor
US9566307B2 (en) 2012-04-19 2017-02-14 Kyushu University, National University Corporation Pharmaceutical composition
MX2014014831A (es) 2012-06-08 2015-02-12 Hoffmann La Roche Selectividad de mutante y combinaciones de un compuesto inhibidor de fosfoinositida 3 cinasa y agentes quimioterapeuticos para el tratamiento de cancer.
MX2015001399A (es) 2012-08-02 2015-09-07 Genentech Inc Anticuerpos anti-etbr e inmunoconjugados.
MX2015001407A (es) 2012-08-02 2015-05-08 Genentech Inc Inmunoconjugados y anticuerpos anti-etbr.
KR20150038068A (ko) * 2012-08-17 2015-04-08 에프. 호프만-라 로슈 아게 코비메티닙 및 베무라피닙을 투여함을 포함하는 흑색종의 조합 치료법
CN105246508A (zh) * 2013-03-14 2016-01-13 基因泰克公司 Mek抑制剂化合物与her3/egfr抑制剂化合物的组合及使用方法
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
DK3698790T3 (da) * 2014-02-07 2023-06-19 Verastem Inc Fremgangsmåder til behandling af abnorm cellevækst
CN106573060A (zh) 2014-07-15 2017-04-19 豪夫迈·罗氏有限公司 使用pd‑1轴结合拮抗剂和mek抑制剂治疗癌症的组合物
CN107073066B (zh) * 2014-09-11 2021-09-17 加利福尼亚大学董事会 mTORC1抑制剂
US11234986B2 (en) 2018-09-11 2022-02-01 Curis, Inc. Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
CN110420330B (zh) * 2019-07-19 2020-05-29 南京医科大学 一种pi3k与mth1靶向药组合物的制药用途
JP2022547358A (ja) 2019-09-13 2022-11-14 ジ インスティテュート オブ キャンサー リサーチ:ロイヤル キャンサー ホスピタル 治療組成物、組み合わせ、及び使用方法
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470356A1 (de) * 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
BE754606A (fr) * 1969-08-08 1971-02-08 Thomae Gmbh Dr K Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication
BE759493A (fr) * 1969-11-26 1971-05-25 Thomae Gmbh Dr K Nouvelles 2-(5-nitro-2-furyl)-thieno(3,2-d) pyrimidines et procedes pour les fabriquer
US3763156A (en) * 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
CH592668A5 (cg-RX-API-DMAC10.html) * 1973-10-02 1977-10-31 Delalande Sa
GB1570494A (en) * 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
US4510139A (en) * 1984-01-06 1985-04-09 Sterling Drug Inc. Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity
BR9507203A (pt) * 1994-04-01 1997-09-09 Shionogi & Co Derivado de oxima e bactericida que contém o mesmo como ingredientes ativo
US6974878B2 (en) * 2001-03-21 2005-12-13 Symyx Technologies, Inc. Catalyst ligands, catalytic metal complexes and processes using same
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
US7498304B2 (en) * 2000-06-16 2009-03-03 Curis, Inc. Angiogenesis-modulating compositions and uses
CN1219753C (zh) * 2000-07-19 2005-09-21 沃尼尔·朗伯公司 4-碘苯氨基苯氧肟酸的氧合酯
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
CA2517517C (en) * 2003-03-03 2012-12-18 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US20050049276A1 (en) * 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
US7144907B2 (en) * 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7538120B2 (en) * 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US8084645B2 (en) * 2003-09-19 2011-12-27 Chugai Seiyaku Kabushiki Kaisha 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors
US7517994B2 (en) * 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
NZ567140A (en) * 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
CL2007001165A1 (es) 2006-04-26 2008-01-25 Hoffmann La Roche 2-(1h-indazol-4-il)-6-(4-metanosulfonil-piperazin-1-ilmetil)-4-morfolin-4-il-tieno[3,2-d]pirimidina; procedimiento de preparacion; composicion farmaceutica; proceso de preparacion de dicha composicion; kit farmaceutico; y uso para tratar enfermedades tales como cancer, desordenes inmunes y enfermedades cardiovasculares.
CA2658725A1 (en) * 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
AR064155A1 (es) * 2006-12-07 2009-03-18 Piramed Ltd Compuestos de inhibidores de fosfoinositido-3 quinasa y metodos de uso
CA2699202C (en) 2007-09-12 2016-09-27 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
CN103841976A (zh) * 2011-04-01 2014-06-04 基因泰克公司 Akt和mek抑制剂化合物的组合及其使用方法

Similar Documents

Publication Publication Date Title
JP2013507415A5 (cg-RX-API-DMAC10.html)
JP2016525097A5 (cg-RX-API-DMAC10.html)
JP2013542247A5 (cg-RX-API-DMAC10.html)
JP2006182786A5 (cg-RX-API-DMAC10.html)
JP2017537126A5 (cg-RX-API-DMAC10.html)
HRP20191617T1 (hr) Kombinacija koja sadrži inhibitor mek i inhibitor b-raf
JP2006523216A5 (cg-RX-API-DMAC10.html)
JP2005525345A5 (cg-RX-API-DMAC10.html)
FI3504187T3 (fi) Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
JP2018526376A5 (cg-RX-API-DMAC10.html)
JP2014532647A5 (cg-RX-API-DMAC10.html)
JP2015523397A5 (cg-RX-API-DMAC10.html)
RU2012118974A (ru) Комбинации ингибитора pi3k и ингибитора мек
JP2014526503A5 (cg-RX-API-DMAC10.html)
JP2014521735A5 (cg-RX-API-DMAC10.html)
JP2008521928A5 (cg-RX-API-DMAC10.html)
JP2019511526A5 (cg-RX-API-DMAC10.html)
JP2012525393A5 (cg-RX-API-DMAC10.html)
JP2011507896A5 (cg-RX-API-DMAC10.html)
NZ601595A (en) Oral formulations and lipophilic salts of methylnaltrexone
EA037152B1 (ru) Способ лечения рака
RU2014135436A (ru) Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака
JP2014505107A5 (cg-RX-API-DMAC10.html)
JP2016529285A5 (cg-RX-API-DMAC10.html)
JP2018090566A5 (cg-RX-API-DMAC10.html)